Mironid Attendind Bio€quity Europe 2025

Our Chief Executive Officer Neil Wilkie will be in Bruges, Belgium, from 12-14 May at Bio€quity Europe, an opportunity to meet with potential investors to discuss the current issues and trends facing the biotech industry and how to rise above the noise to attract the right investors and partnerships.

If you would like to meet Neil or further discuss the work Mironid is doing to transform the treatment landscape for Autosomal Dominant Polycystic Kidney Disease (ADPKD), please get in touch at: enquiries@mironid.com

The Latest

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney diseaseAugust 5, 2026

Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces it has raised $46 million in a Series B funding round. Neil Wilkie, CEO of Mironid said: “ADPKD is the [...]

Mironid Raises Awareness for PKD with 1,000 km Team ChallengeApril 14, 2026

At Mironid, we’re proud to support causes that make a meaningful difference. Last month, our team took part in the Polycystic Kidney Disease (PKD) Charity UK‘s ‘Spring into March’ challenge, raising awareness and supporting the [...]

Q&A with David Henderson, Head of BiologyMarch 19, 2026

ADPKD is a devastating disease that affects more than 12 million people worldwide. Over the past decade, there has been important progress in our understanding of the disease, with meaningful steps forward for both patients and clinicians. However, significant challenges remain. Tolerability [...]